C Prego1, M Fabre, D Torres, M J Alonso. 1. Department of Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela (USC), Campus Sur, 15782, Santiago de Compostela, Spain.
Abstract
PURPOSE: We have previously shown that high molecular weight (MW > 100 kDa) chitosan nanocapsules are efficient vehicles for improving the oral absorption of salmon calcitonin (sCT). In the present work, our objectives were, first, to investigate the influence of some formulation parameters on the efficacy of chitosan nanocapsules as carriers for the oral administration of sCT and, second, to elucidate the mechanism of interaction of chitosan nanocapsules with intestinal model cell lines. METHODS: sCT-loaded chitosan nanocapsules were prepared by the solvent displacement technique. They were characterized for their size, zeta potential, and sCT loading. The ability of chitosan nanocapsules to enhance the oral absorption of sCT was investigated in rats by monitoring the serum calcium levels. Finally, the mechanism of interaction of chitosan nanocapsules with the Caco-2 cell model or in the coculture of Caco-2 with HT29-M6 cells was investigated by confocal fluorescence microscopy. RESULTS: Chitosan nanocapsules presented a particle size in nanometer range, a positive surface charge, and an efficient encapsulation of sCT. Following oral administration to rats, all formulations of nanocapsules exhibited the ability to reduce calcemia levels; however, the intensity of the response varied depending on the formulation conditions. With regard to the mechanism of interaction of chitosan nanocapsules with cell culture, the xz images evidenced that chitosan nanocapsules interact and remain associated to the apical side of both model cell cultures. In addition, chitosan nanocapsules showed a preferable association to the mucus-secreting cells (HT29-M6). CONCLUSIONS: Chitosan nanocapsules are able to enhance and prolong the intestinal absorption of sCT and this effect could be mainly ascribed to their mucoadhesive character and intimate interaction with the intestinal barrier.
PURPOSE: We have previously shown that high molecular weight (MW > 100 kDa) chitosan nanocapsules are efficient vehicles for improving the oral absorption of salmon calcitonin (sCT). In the present work, our objectives were, first, to investigate the influence of some formulation parameters on the efficacy of chitosan nanocapsules as carriers for the oral administration of sCT and, second, to elucidate the mechanism of interaction of chitosan nanocapsules with intestinal model cell lines. METHODS: sCT-loaded chitosan nanocapsules were prepared by the solvent displacement technique. They were characterized for their size, zeta potential, and sCT loading. The ability of chitosan nanocapsules to enhance the oral absorption of sCT was investigated in rats by monitoring the serum calcium levels. Finally, the mechanism of interaction of chitosan nanocapsules with the Caco-2 cell model or in the coculture of Caco-2 with HT29-M6 cells was investigated by confocal fluorescence microscopy. RESULTS:Chitosan nanocapsules presented a particle size in nanometer range, a positive surface charge, and an efficient encapsulation of sCT. Following oral administration to rats, all formulations of nanocapsules exhibited the ability to reduce calcemia levels; however, the intensity of the response varied depending on the formulation conditions. With regard to the mechanism of interaction of chitosan nanocapsules with cell culture, the xz images evidenced that chitosan nanocapsules interact and remain associated to the apical side of both model cell cultures. In addition, chitosan nanocapsules showed a preferable association to the mucus-secreting cells (HT29-M6). CONCLUSIONS:Chitosan nanocapsules are able to enhance and prolong the intestinal absorption of sCT and this effect could be mainly ascribed to their mucoadhesive character and intimate interaction with the intestinal barrier.
Authors: Ana Vila; Alejandro Sánchez; Kevin Janes; Isabel Behrens; Thomas Kissel; José Luis Vila Jato; María José Alonso Journal: Eur J Pharm Biopharm Date: 2004-01 Impact factor: 5.571
Authors: Ahmed O Elzoghby; Shaimaa K Mostafa; Maged W Helmy; Maha A ElDemellawy; Salah A Sheweita Journal: Pharm Res Date: 2017-06-22 Impact factor: 4.200
Authors: Thomas P Dooley; April L Ellis; Maria Belousova; Don Petersen; Arthur A DeCarlo Journal: J Biomater Sci Polym Ed Date: 2012-08-13 Impact factor: 3.517
Authors: Paola Sánchez-Moreno; Juan Luis Ortega-Vinuesa; Antonio Martín-Rodríguez; Houría Boulaiz; Juan Antonio Marchal-Corrales; José Manuel Peula-García Journal: Int J Mol Sci Date: 2012-02-22 Impact factor: 6.208
Authors: M Kaiser; S Pereira; L Pohl; S Ketelhut; B Kemper; C Gorzelanny; H-J Galla; B M Moerschbacher; F M Goycoolea Journal: Sci Rep Date: 2015-05-13 Impact factor: 4.379